An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

PHASE3CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

September 23, 2024

Study Completion Date

September 23, 2024

Conditions
Schizophrenia
Interventions
DRUG

SEP-363856

SEP-363856 tablet

Trial Locations (16)

20877

Research Site, Gaithersburg

28211

Research Site, Charlotte

28601

Research Site, Hickory

30318

Research Site, Atlanta

30331

Research Site, Atlanta

33021

Research Site, Hollywood

33122

Research Site, Miami

60640

Research Site, Chicago

75080

Research Site, Richardson

90502

Research Site, Torrance

90706

Research Site, Bellflower

91945

Research Site, Lemon Grove

92071

Research Site, Santee

92805

Research Site, Anaheim

92845

Research Site, Garden Grove

08009

Research Site, Berlin

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY